Onercept. Serono

dc.contributor.authorNikas, S. N.en
dc.contributor.authorDrosos, A. A.en
dc.date.accessioned2015-11-24T19:00:55Z
dc.date.available2015-11-24T19:00:55Z
dc.identifier.issn1472-4472-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19617
dc.rightsDefault Licence-
dc.subjectAnimalsen
dc.subject*Anti-Inflammatory Agents, Non-Steroidal/chemistry/pharmacokinetics/therapeuticen
dc.subjectuseen
dc.subject*Carrier Proteins/chemistry/pharmacokinetics/therapeutic useen
dc.subjectClinical Trials, Phase I as Topicen
dc.subjectClinical Trials, Phase II as Topicen
dc.subjectCrohn Disease/*drug therapyen
dc.subjectHalf-Lifeen
dc.subjectHumansen
dc.subjectPsoriasis/*drug therapyen
dc.subject*Receptors, Tumor Necrosis Factoren
dc.subjectReceptors, Tumor Necrosis Factor, Type Ien
dc.subjectStructure-Activity Relationshipen
dc.subjectTreatment Outcomeen
dc.subjectTumor Necrosis Factor Decoy Receptorsen
dc.titleOnercept. Seronoen
heal.abstractOnercept is a recombinant human soluble p55 tumor necrosis factor binding protein under development by Serono for the potential treatment of a number of disorders, including Crohn's disease, psoriasis and psoriatic arthritis. In March 2002, phase II trials were ongoing for these indications, and in February 2003, Serono expected phase III trials in psoriatic arthritis to commence in the second half of 2003.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/14758777-
heal.journalNameCurr Opin Investig Drugsen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2003-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: